EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association of antiseizure medications and adverse cardiovascular events: A global health federated network analysis

Josephine Mayer iD, Gashirai K Mbizvo iD, Tommaso Bucci, Anthony Marson, Gregory Y H Lip

Epilepsia · 2024-05 · 65 (5) · 1264-1274

DOI: 10.1111/epi.17922 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, online erschienen am 27.02.2024. Verfasst von Josephine Mayer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Liverpool Centre of Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpo…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Anticonvulsants, Epilepsy, Carbamazepine. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

A diagnosis of epilepsy has been associated with adverse cardiovascular events (CEs), but the extent to which antiseizure medications (ASMs) may contribute to this is not well understood. The aim of this study was to compare the risk of adverse CEs associated with ASM in patients with epilepsy (PWE).

Methods

A retrospective case–control cohort study was conducted using TriNetX, a global health federated network of anonymized patient records. Patients older than 18 years, with a diagnosis of epilepsy (International Classification of Diseases, 10th Revision code G40) and a medication code of carbamazepine, lamotrigine, or valproate were compared. Patients with cardiovascular disease prior to the diagnosis of epilepsy were excluded. Cohorts were 1:1 propensity score matched (PSM) according to age, sex, ethnicity, hypertension, heart failure, atherosclerotic heart disease, atrial and cardiac arrythmias, diabetes, disorders of lipoprotein metabolism, obesity, schizophrenia and bipolar disorder, medications, and epilepsy classification. The primary outcome was a composite of adverse CEs (ischemic stroke, acute ischemic heart disease, and heart failure) at 10 years. Cox regression analyses were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) following 1:1 PSM.

Results

Of 374 950 PWE included; three cohorts were established after PSM: (1) carbamazepine compared to lamotrigine, n = 4722, mean age 37.4 years; (2) valproate compared to lamotrigine, n = 5478, mean age 33.9 years; and (3) valproate compared to carbamazepine, n = 4544, mean age 37.0 years. Carbamazepine and valproate use were associated with significantly higher risk of composite cardiovascular outcome compared to lamotrigine (HR = 1.390, 95% CI = 1.160–1.665 and HR = 1.264, 95% CI = 1.050–1.521, respectively). Valproate was associated with a 10‐year higher risk of all‐cause death than carbamazepine (HR = 1.226, 95% CI = 1.017–1.478), but risk of other events was not significantly different. Significance Carbamazepine and valproate were associated with increased CE risks compared to lamotrigine. Cardiovascular risk factor monitoring and careful follow‐up should be considered for these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesAnticonvulsantsEpilepsyCarbamazepineLamotrigineHumansFemaleMaleMiddle AgedRetrospective StudiesAdultCase-Control StudiesAgedValproic AcidGlobal HealthCohort Studies

Stichwörter der Autor:innen

carbamazepineepilepsylamotriginestrokevalproate

Substanzen

AnticonvulsantsCarbamazepineLamotrigineValproic Acid

Autor:innen und Institutionen

  • Liverpool Centre of Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, UK.
  • Department of Pharmacology and Therapeutics, Institute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool, UK.
  • Department of Neurology, The Walton Centre, National Health Service Foundation Trust, Liverpool, UK.
  • Department of General and Specialized Surgery, Sapienza University of Rome, Rome, Italy.
  • Department of Clinical Medicine, Danish Center for Health Services Research, Aalborg University, Aalborg, Denmark.

ORCID-Profile: Josephine Mayer, Gashirai K Mbizvo

Zitieren

APA

Mayer, J., Mbizvo, G. K., Bucci, T., Marson, A., & Lip, G. Y. H. (2024). Association of antiseizure medications and adverse cardiovascular events: A global health federated network analysis. Epilepsia, 65(5), 1264-1274. https://doi.org/10.1111/epi.17922

Vancouver

Mayer J, Mbizvo GK, Bucci T, Marson A, Lip GYH. Association of antiseizure medications and adverse cardiovascular events: A global health federated network analysis. Epilepsia. 2024;65(5):1264-1274. doi:10.1111/epi.17922

BibTeX
@article{Mayer2024,
  author = {Mayer, Josephine and Mbizvo, Gashirai K and Bucci, Tommaso and Marson, Anthony and Lip, Gregory Y H},
  title = {Association of antiseizure medications and adverse cardiovascular events: A global health federated network analysis},
  journal = {Epilepsia},
  year = {2024},
  volume = {65},
  number = {5},
  pages = {1264--1274},
  doi = {10.1111/epi.17922}
}
Kostenlos starten →